Med Care 43:1203–1207PubMedCrossRef 9. Byer B, Myers LB (2000) Psychological correlates of adherence to medication in asthma. Psychol Health Med 5:389–393CrossRef 10. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J (2004) Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 15:38–44PubMedCrossRef 11. Kendler DL, Bessette L, Hill CD et al (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837–846PubMedCrossRef 12. Fallowfield L, Atkins L, Catt S et al (2006) Patients’ preference for administration

of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol ISRIB supplier 17:205–210PubMedCrossRef 13. Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM (2006) An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 90:217–221PubMedCrossRef

14. Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing BAY 1895344 in vivo frequency: understanding the relationship. Bone 38:S2–S6PubMedCrossRef 15. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618–625PubMedCrossRef 16. Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled CHIR-99021 molecular weight study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res

19:1059–1066PubMedCrossRef 17. McClung MR, Lewiecki EM, Cohen SB et al (2006) PF-6463922 order denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef 18. Lewiecki EM, Miller PD, McClung MR et al (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832–1841PubMedCrossRef 19. Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161PubMedCrossRef 20. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef 21. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725–1735 22. Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1–24CrossRef 23. Gold DT, Horne R, Hill C, Borenstein J, Varon S, Macarios D (2008) Development, reliability, and validity of a new preference satisfaction questionnaire (PSQ). J Bone Miner Res 23:S210–S211 24.